GRACE

Real-World Experience Study of an Active Drug For the Treatment of Endometriosis in Canada

Brief summary

The objective of this study is to evaluate real-world effectiveness of an active drug in Canadian women with endometriosis.

Observational

Observational study

Status:
Completed
Conditions:
Endometriosis
Enrollment:
100 patients
Protocol ID:
P19-933
Observational model:
Cohort
Time perspective:
Prospective

 

Eligibility criteria

Participant attributes:
Female

Age:

From 18 Years to 50 Years.

Inclusion Criteria:

- Prescribed elagolix as part of standard treatment

- Naive to elagolix prior to starting this study or have stopped taking elagolix for 2
months prior to the start of this study

- Symptomatic endometriosis (clinically or surgically diagnosed) including currently
experiencing dysmenorrhea

- Has provided written informed consent allowing the use of their data for the study

Exclusion Criteria:

- Did not consent

- Cannot fill out questionnaires

- Prescribed elagolix for a period of 1 or 2 months only

- Post-menopausal (naturally or surgically)

- Symptomatic uterine fibroid(s)

- Had medical treatment for uterine fibroids (any length of treatment)

All the cities where the clinical studies are located

Lasalle - H8N 1T9

More information about this study

clinicaltrials.gov